PUBLISHER: The Business Research Company | PRODUCT CODE: 1825523
PUBLISHER: The Business Research Company | PRODUCT CODE: 1825523
Primary cells refer to cells extracted directly from the living tissues of animals or people and then treated to prepare them for use in suitable cell treatments. These cells are employed in various applications, including 3D cell cultivation, virology, cancer research, stem cell treatment, and tissue restoration.
The main types of primary cells are hematopoietic cells, dermatophytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and others. Hematopoietic cells are a type of stem cell that gives rise to the various blood cell types in the body. Its origins are human primary cells and animal primary cells, and its end users are pharmaceuticals, biotechnology companies, contract research organizations (CROs), academic and research institutes, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The main types of primary cells are hematopoietic cells, dermatophytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and others. Hematopoietic cells are a type of stem cell that gives rise to the various blood cell types in the body. Its origins are human primary cells and animal primary cells, and its end users are pharmaceuticals, biotechnology companies, contract research organizations (CROs), academic and research institutes, and others.
The primary cells market size has grown rapidly in recent years. It will grow from $1.49 billion in 2024 to $1.67 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising prevalence of cancer, increasing investments in regenerative medicine research, growing demand for monoclonal antibodies, advantages of primary human cells over cell lines, increasing prevalence of chronic diseases.
The primary cells market size is expected to see rapid growth in the next few years. It will grow to $2.44 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, growing focus on stem cell research, rising investments, increasing adoption of cell-based assays. Major trends in the forecast period include demand for human primary cells, advancements in research tools and technologies, adoption of cell-based therapies.
The forecast of 10.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. biomedical research by increasing costs for high-quality primary cell lines imported from the UK and Canada, potentially compromising drug development timelines and raising lab expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising government funding for cancer research is expected to propel the growth of the primary cells market going forward. Funding refers to the financial support provided to a project, initiative, organization, or individual to enable its development, operation, or achievement of specific goals. Government funding is used in primary cells to support research projects, personnel support, equipment and infrastructure, training and education, regulatory compliance, and technology development. For instance, in May 2022, the American Institute for Cancer Research (AICR), a US-based large American cancer research organization, requested $49 billion funding in 2023, which is an increase of $4.1 billion compared to the previous year's $46.4 billion. Therefore, rising government funding for cancer research is expected to propel the growth of the primary cell market.
Leading companies in the primary cell market are focusing on innovations in cell products, including cell culture and stem cell products, to drive progress in research and therapeutic development. Serum-free medium, for example, is a type of growth medium for cell or tissue cultures that excludes animal-derived serums, such as fetal bovine serum (FBS). In July 2024, Bioserve Biotechnologies (India) Private Ltd., an Indian company specializing in biotechnology and life sciences solutions, introduced advanced stem cell products from REPROCELL to the Indian market. These new products aim to foster advancements in scientific research and drug development, contributing to growth in regenerative medicine and therapeutic discovery in the region.
In April 2023, AnaBios Corporation, a US-based biotechnology company, acquired Cell Systems for an undisclosed amount. This acquisition was aimed at expanding AnaBios' unique human tissue and cell portfolio, providing enhanced translational tools and reagents to academic, pharmaceutical, and biotech researchers, and optimizing research programs through enhanced human insights. Cell Systems is a US-based biotechnology company that specializes in providing human primary cells and cell culture media.
Major companies operating in the primary cells market are Thermo Fisher Scientific Inc, Merck KGaA, BD Biosciences, Corning Incorporated, Cytiva, Lonza Group Ltd, Charles River Laboratories Inc., STEMCELL Technologies Inc, American Type Culture Collection, Cell Signaling Technology, BioIVT, InvivoGen, HemaCare Corporation, Creative Bioarray Inc., PromoCell GmbH, CellGenix, AllCells LLC, Axol Bioscience Ltd, PBS Biotech Inc, AnaBios Corporation, ReachBio Research Labs, PELOBIOTECH GmbH, Cell Biologics Inc., ZenBio Inc., StemBioSys Inc
North America was the largest region in the primary cells market in 2024. The regions covered in the primary cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the primary cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary cells market consists of revenues earned by entities by providing services such as cell isolation services, primary cell culture services, cell characterization, and authentication. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary cell market also includes sales of cell culture media and reagents, cell culture plates and flasks, cell isolation kits, and transfection reagents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Primary Cells Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on primary cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for primary cells ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The primary cells market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.